Novo Submits New Application for Its Investigational SubQ Hemophilia Therapy
Novo Nordisk has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for Mim8 (denecimig), an investigational bispecific antibody therapy. The antibody promotes coagulation by binding two key proteins (…
Discover a Treatment Option from HEMA Biologics for the Hemophilia Community
Speakers: Guy Young, MDDescription: Join Dr. Young, speaking on behalf of HEMA Biologics, for an informative conversation about a treatment option for hemophilia A or B with inhibitors. This session will share…
Samantha Short
Evan Rahaeuser
Heather Conner
Amy Walker
Star Therapeutics Announces New Financing for Investigational VWD Treatment
Star Therapeutics recently announced new financing totaling $125 million that will help the San Francisco-based biotechnology company continue to develop their investigational von Willebrand disease therapy VGA039. The U.S. Food and Drug…
MASAC Document 292 - National Bleeding Disorder Clinical Practice Recommendations on the Off-Label Use of Emicizumab for the Treatment of Acquired Hemophilia A
 Experts: Ming Y. Lim1, Peter Kouides2, Magdalena D. Lewandowska3, Jonathan C. Roberts4,5, Amy Dunn6 Affiliations:1Utah Center for Bleeding & Clotting Disorders at University of Utah Health, Salt Lake…
MASAC Document 293 - Recommendation on the Use and Management of Anti-Tissue Factor Pathway Inhibitors in Hemophilia
CHAPTER 1 Recommendation on the Use and Management of Anti-Tissue Factor Pathway Inhibitors in Hemophilia EXPERTS:  Magdalena D Lewandowska MD 1, Janice Staber MD2, Glaivy Batsuli MD3, Rose Bender4…
MASAC Document 294 - Recommendations for the Role of Social Workers in Hemophilia Treatment Centers in the United States
 NATIONAL BLEEDING DISORDERS CLINICAL PRACTICE RECOMMENDATIONS FOR HEMOPHILIA TREATMENT CENTER (HTC) SOCIAL WORKERS  RECOMMENDATIONS FOR THE ROLE OF SOCIAL WORKERS IN HEMOPHILIA TREATMENT CENTERS IN THE UNITED STATES…